Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Multiple Myeloma
Multiple Myeloma
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
Thu, 09/17/20 - 11:09 pm
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in
Endpoints
Fri, 08/21/20 - 12:32 pm
JNJ
Darzalex
FDA
Multiple Myeloma
FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant
Endpoints
Wed, 08/5/20 - 11:24 pm
GSK
FDA
Multiple Myeloma
belantamab mafodotin
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Thu, 07/30/20 - 12:01 am
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
FDA AdCom votes unanimously in favor of GSK myeloma drug, despite earlier agency skepticism
MedCity News
Tue, 07/14/20 - 11:22 pm
GSK
Multiple Myeloma
FDA
belantamab mafodotin
advisory panel
5 FDA approval decisions to watch in the 3rd quarter
BioPharma Dive
Thu, 07/9/20 - 11:09 am
FDA
Gilead Sciences
filgotinib
rheumatoid arthritis
GSK
belantamab mafodotin
Multiple Myeloma
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold
Fierce Biotech
Tue, 07/7/20 - 10:39 am
Cellectis
CAR-T
UCARCS1A
Multiple Myeloma
patient deaths
FDA
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
MedCity News
Thu, 06/25/20 - 10:36 am
belantamab mafodotin
GSK
Multiple Myeloma
FDA
advisory panels
GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight
Endpoints
Wed, 05/27/20 - 10:54 am
GSK
ASCO 2020
antibody-drug conjugate
belantamab mafodotin
Multiple Myeloma
Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results
Motley Fool
Tue, 05/19/20 - 11:30 pm
JNJ
Multiple Myeloma
bispecific antibodies
JNJ-5957
teclistamab
clinical trials
Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
BioSpace
Mon, 05/18/20 - 10:37 am
JNJ
Janssen
teclistamab
JNJ-7957
clinical trials
ASCO 2020
Multiple Myeloma
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Sanofi takes aim at J&J's myeloma star Darzalex with latest Sarclisa trial win
Fierce Pharma
Tue, 05/12/20 - 12:01 pm
Sanofi
Sarclisa
Multiple Myeloma
Amgen
Kyprolis
J&J defends Darzalex with FDA approval for faster dosing
Pharmaforum
Sun, 05/3/20 - 08:04 pm
JNJ
FDA
Darzalex
dosing
Multiple Myeloma
2 newer multiple myeloma drugs fall short in bid for wider market
BioPharma Dive
Tue, 03/10/20 - 11:58 am
Multiple Myeloma
clinical trials
Bristol-Myers Squibb
Takeda
Ninlaro
Empliciti
Revlimid
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Mon, 03/9/20 - 10:52 am
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Karyopharm posts positive data from Phase III trial of multiple myeloma drug
MedCity News
Thu, 03/5/20 - 10:56 am
Karyopharm
Multiple Myeloma
clinical trials
Xpovio
FDA Greenlights Sanofi's Sarclisa for Multiple Myeloma
BioSpace
Tue, 03/3/20 - 10:53 am
FDA
Sarclisa
Sanofi
Multiple Myeloma
Johnson & Johnson Submits FDA Application for Multiple Myeloma Drug
Motley Fool
Mon, 02/10/20 - 11:32 pm
JNJ
Janssen
Darzalex
daratumumab
Multiple Myeloma
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
Fierce Biotech
Mon, 02/10/20 - 10:11 am
CAR-T
Multiple Myeloma
CD229
JNJ
Bluebird Bio
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »